Pharmacologic Blockade of FAK Autophosphorylation Decreases Human Glioblastoma Tumor Growth and Synergizes with Temozolomide

Malignant gliomas are characterized by aggressive tumor growth with a mean survival of 15 to 18 months and frequently developed resistance to temozolomide. Therefore, strategies that sensitize glioma cells to temozolomide have a high translational impact. We have studied focal adhesion kinase (FAK), a tyrosine kinase and emerging therapeutic target that is known to be highly expressed and activated in glioma. In this report, we tested the FAK autophosphorylation inhibitor, Y15, in DBTRG and U87 glioblastoma cells. Y15 significantly decreased viability and clonogenicity in a dose-dependent manner, increased detachment in a dose- and time-dependent manner, caused apoptosis, and inhibited cell invasion in both cell lines. In addition, Y15 treatment decreased autophosphorylation of FAK in a dose-dependent manner and changed cell morphology by causing cell rounding in DBTRG and U87 cells. Administration of Y15 significantly decreased subcutaneous DBTRG tumor growth with decreased Y397-FAK autophosphorylation, activated caspase-3 and PARP. Y15 was administered in an orthotopic glioma model, leading to an increase in mouse survival. The combination of Y15 with temozolomide was more effective than either agent alone in decreasing viability and activating caspase-8 in DBTRG and U87 cells in vitro. In addition, the combination of Y15 and temozolomide synergistically blocked U87 brain tumor growth in vivo. Thus, pharmacologic blockade of FAK autophosphorylation with the oral administration of a small-molecule inhibitor Y15 has a potential to be an effective therapy approach for glioblastoma either alone or in combination with chemotherapy agents such as temozolomide. Mol Cancer Ther; 12(2); 162–72. ©2012 AACR.

[1]  H. Chun,et al.  Conditional deletion of the focal adhesion kinase FAK alters remodeling of the blood-brain barrier in glioma. , 2010, Cancer research.

[2]  V. Golubovskaya,et al.  Focal adhesion kinase and p53 signal transduction pathways in cancer. , 2010, Frontiers in bioscience.

[3]  G. Mcmahon,et al.  Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models , 2010, Cancer biology & therapy.

[4]  G. Mcmahon,et al.  PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments , 2010, Cancer biology & therapy.

[5]  V. Golubovskaya,et al.  Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma , 2010, Cell cycle.

[6]  A. Magis,et al.  A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer , 2009, Cell cycle.

[7]  A. Magis,et al.  A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. , 2008, Journal of medicinal chemistry.

[8]  V. Golubovskaya,et al.  FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. , 2008, Carcinogenesis.

[9]  V. Golubovskaya,et al.  Focal Adhesion Kinase Versus p53: Apoptosis or Survival? , 2008, Science Signaling.

[10]  H. Pitot,et al.  p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. , 2008, Cancer research.

[11]  Matthew D. Wessel,et al.  Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. , 2008, Cancer research.

[12]  W. Yung,et al.  Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo , 2007, Molecular Cancer Therapeutics.

[13]  W. Franklin,et al.  Characterization of a continuous human glioma cell line DBTRG-05MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses , 1992, In Vitro Cellular & Developmental Biology - Animal.

[14]  V. Golubovskaya,et al.  Focal adhesion kinase and p53 signaling in cancer cells. , 2007, International review of cytology.

[15]  E. Golemis,et al.  HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells , 2007, Oncogene.

[16]  E. Golemis,et al.  HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells , 2006, Oncogene.

[17]  M. Nguyen,et al.  Reduced Glioma Infiltration in Src-deficient Mice , 2006, Journal of Neuro-Oncology.

[18]  V. Golubovskaya,et al.  Direct Interaction of the N-terminal Domain of Focal Adhesion Kinase with the N-terminal Transactivation Domain of p53* , 2005, Journal of Biological Chemistry.

[19]  V. Golubovskaya,et al.  Dual Inhibition of Focal Adhesion Kinase and Epidermal Growth Factor Receptor Pathways Cooperatively Induces Death Receptor-mediated Apoptosis in Human Breast Cancer Cells* , 2002, The Journal of Biological Chemistry.

[20]  G. Gillespie,et al.  Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples. , 2002, Cancer research.

[21]  P. Schwartzberg,et al.  Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. , 1999, Molecular cell.

[22]  D. Schlaepfer,et al.  Signaling through focal adhesion kinase. , 1999, Progress in biophysics and molecular biology.